Effect of 6-aminonicotinamide on metabolism of astrocytes and C6-glioma cells.
Brain tissue cells have been shown to use two predominant pathways for energy production. The first of these is the pentose phosphate shunt, and the second is glycolysis, followed by the TCA cycle. Inhibition of these pathways can result in a reduction of ATP, and changes in the concentration of various metabolites. In the present study, the acute and chronic effect of 6-aminonicotinamide (6-AN) (0.01, 0.02, and 0.03 mg/ml) was examined on astrocytes and C6-glioma cells. Following this treatment, glucose, lactate, glutamate, ATP, and PCr were assayed according to the procedures of Lowry and Passonneau. Our data indicated that following 15 minutes treatment of astrocytes and C6-glioma with 6AN there was no significant difference in the concentration of metabolites measured. However, following 24 hours treatment there was a significant increase in glucose concentration and significant reduction in the concentration of ATP, PCr, lactate and glutamate in both cell types. Morphological changes appeared later following 48 hours treatment with 6-AN in both cell types. Glucose accumulation can be explained by the fact that it is the precursor to both glycolysis and the pentose phosphate shunt. If these processes are inhibited, glucose will obviously accumulate and products like ATP, PCr, lactate and glutamate will decrease. Additionally, there was significant differences in concentration of glucose and lactate between astrocytes and C6-glioma cells. The significance of these differences has been discussed.
Haghighat
N
N
Department of Cell Biology and Anatomy, Finch University of Health Sciences, Chicago Medical School, North Chicago, IL 60064, USA.
McCandless
D W
DW
D015120:6-Aminonicotinamide / Q000494:pharmacology*; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D001932:Brain Neoplasms / Q000378:metabolism* / Q000648:ultrastructure; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005910:Glioma / Q000378:metabolism* / Q000648:ultrastructure; D005947:Glucose / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism; D019344:Lactic Acid / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000378:metabolism; D010725:Phosphocreatine / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D014407:Tumor Cells, Cultured
D004791:Enzyme Inhibitors; D009419:Nerve Tissue Proteins; D010725:Phosphocreatine; D015120:6-Aminonicotinamide; D019344:Lactic Acid; D018698:Glutamic Acid; D000255:Adenosine Triphosphate; D005947:Glucose